Aptevo Therapeutics provided an overview of its solid tumor anti-cancer compound APVO603, which is currently in preclinical development. APVO603 is a novel bispecific antibody designed to enhance anti-tumor immune responses through dual targeting of 4-1BB (CD137) and OX40 (CD134). These are two key co-stimulatory receptors involved in T cell and NK cell activation.
The company continues its focus on developing bispecific anti-cancer agents with differentiated mechanisms of action, leveraging its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies. APVO603 exemplifies this strategy by aiming to provide a potent and targeted immunotherapy for solid tumors.
By simultaneously engaging both 4-1BB and OX40, APVO603 is engineered to amplify the immune system's ability to combat cancer cells. This dual-targeting approach seeks to overcome limitations of single-target therapies and improve outcomes for patients with challenging solid tumors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.